Estrogen replacement therapy following treatment for stage I endometrial carcinoma

Gynecol Oncol. 1990 Feb;36(2):189-91. doi: 10.1016/0090-8258(90)90171-g.


One hundred forty-four patients with clinical stage I endometrial adenocarcinoma were treated over an 11-year period at Madigan Army Medical Center and Brooke Army Medical Center. Following surgical staging, 44 selected patients were placed on oral estrogen replacement for a median duration of 64 months. In the estrogen user group, there were no recurrent endometrial cancer and no intercurrent death. Of the 99 nonestrogen users, there were 8 recurrences (8%) and 8 intercurrent deaths. Patients placed on estrogen replacement had low-risk factors for recurrence, namely, low tumor grade (grades 1 and 2), less than 1/2 myometrial invasion, and no metastases to lymph nodes or other organs. Postoperative estrogen replacement appears to be safe in selected low-risk patients.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Estrogens / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Postoperative Care
  • Retrospective Studies
  • Uterine Neoplasms / drug therapy*
  • Uterine Neoplasms / pathology
  • Uterine Neoplasms / surgery


  • Estrogens